Summary & Overview
HCPCS A4100: Non-Sheet Form Skin Substitute, FDA-Cleared Device
HCPCS Level II code A4100 covers non-sheet form skin substitutes that are FDA-cleared as devices and billed in addition to a primary procedure. These products are used as adjunctive therapeutic devices in wound management and reconstructive procedures, making this code relevant across surgical, wound care, and outpatient facility settings nationwide. The designation matters for device billing, coverage determinations, and facility charge capture.
Key payers in the analysis include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find a concise overview of coding context, typical sites of service, and payer coverage focus. The publication summarizes common modifiers and billing considerations, highlights where national payers typically classify these adjunctive skin substitute devices, and outlines clinical contexts in which A4100 is applied (for example, complex wounds, reconstructive adjuncts, and device-supported tissue repair).
This briefing provides operationally relevant benchmarks and payer-policy themes, clarifies the clinical scenarios tied to device use, and identifies gaps where specific payer policies or coding guidance may be required. Data not available in the input is noted where applicable.
Billing Code Overview
HCPCS Level II code A4100 describes a non-sheet form skin substitute that is FDA-cleared as a device and is billed in addition to the primary procedure. This code applies to off-the-shelf or device-based skin substitute products that are not in sheet form and are used to support wound closure, tissue regeneration, or similar reconstructive purposes.
-
Service type: Device-based skin substitute applied adjunctively to a primary surgical or wound-care procedure
-
Typical site of service: Hospital outpatient departments, ambulatory surgical centers, wound care clinics, and other facility settings where adjunctive skin substitute devices are used
Clinical & Coding Specifications
Clinical Context
A 62-year-old patient with a chronic, non-healing lower extremity wound following peripheral vascular disease and prior debridement presents to an outpatient wound care clinic for advanced reconstruction. The clinician evaluates the wound, performs sharp debridement of devitalized tissue, achieves hemostasis, and selects a non-sheet form skin substitute cleared by the FDA as a device to promote granulation and closure. The substitute is applied directly to the prepared wound bed, secured per product instructions, and covered with appropriate dressings. The patient is instructed on offloading, follow-up frequency, and signs of infection. Subsequent visits assess graft take, replace dressings, and may repeat applications of the non-sheet form skin substitute as clinically indicated. Typical multidisciplinary workflow includes the referring vascular surgeon or primary care physician, the wound care specialist (podiatrist, general surgeon, or plastic surgeon), nursing staff for dressing changes, and periodic vascular evaluation if ischemia persists. Typical documentation includes wound measurements, base and exudate description, debridement performed, device lot and manufacturer, application technique, and informed consent for use of an FDA-cleared device.
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|
00 | No modifier — standard reporting | When no additional modifier applies and reporting the service as usual |